• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RLX Technology Announces Unaudited Third Quarter 2023 Financial Results

    11/13/23 4:59:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $RLX alert in real time by email

    BEIJING, Nov. 13, 2023 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading branded e-vapor company in China, today announced its unaudited financial results for the third quarter ended September 30, 2023.

    Third Quarter 2023 Financial Highlights

    • Net revenues were RMB428.1 million (US$58.7 million) in the third quarter of 2023, compared with RMB1,044.4 million in the same period of 2022.
    • Gross margin was 24.7% in the third quarter of 2023, compared with 50.0% in the same period of 2022.
    • U.S. GAAP net income was RMB172.7 million (US$23.7 million) in the third quarter of 2023, compared with RMB505.2 million in the same period of 2022.
    • Non-GAAP net income[1] was RMB197.5 million (US$27.1 million) in the third quarter of 2023, compared with RMB328.6 million in the same period of 2022.

    [1] Non-GAAP net income is a non-GAAP financial measure. For more information on the Company's non-GAAP financial measures, please see the section "Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

    "The end of the third quarter of 2023 marked one year since the new regulatory framework for the e-vapor industry came into effect," said Ms. Ying (Kate) Wang, Co-founder, Chairperson of the Board of Directors, and CEO of RLX Technology. "As a legitimate industry participant, we have remained dedicated to developing our product portfolio to provide adult smokers with compliant, superior-quality products. While we have made some progress with our recovery, we are still facing external challenges, especially the impact of illegal products. We recognize that many users are still unaware of these new regulations, such as flavor restrictions, which has slowed their adoption of the new national standard products. To address these near-term obstacles, we will forge ahead with our core strategy: providing a wide variety of quality, compliant products across an extensive range of price points to meet users' various needs. Meanwhile, we are making efforts to enhance users' understanding of the new regulations and collaborating with regulators to combat illegal products and create a healthy and orderly market. As a trusted e-vapor brand for adult smokers, we believe that more users will gradually switch to our products as increased awareness of the new regulations and the dangers of substandard, illegal products rises."

    Mr. Chao Lu, Chief Financial Officer of RLX Technology, commented, "In the third quarter of 2023, we continued to face significant headwinds due to competition from illegal products. Against this challenging backdrop, we resolutely executed our strategy and focused on improving profitability, which continues to be our top priority. Our strategic cost optimization initiatives have begun to demonstrate positive outcomes, including a consistent reduction in our non-GAAP operating loss and signs of recovery in our non-GAAP net profit margin. Notably, we achieved a second consecutive quarter of positive operating cash flow this quarter, underscoring our business' resilience in the post-regulatory era. Looking forward, we will remain committed to enhancing our financial performance and delivering sustainable value to our shareholders."

    Third Quarter 2023 Financial Results

    Net revenues were RMB428.1 million (US$58.7 million) in the third quarter of 2023, compared with RMB1,044.4 million in the same period of 2022. The decrease was primarily due to the discontinuation of our older products and the competition of illegal products in the market, which resurged after the regulator's special action ended in April 2023.

    Gross profit was RMB105.7 million (US$14.5 million) in the third quarter of 2023, compared with RMB522.0 million in the same period of 2022.

    Gross margin was 24.7% in the third quarter of 2023, compared with 50.0% in the same period of 2022. The decrease was primarily due to the imposition of a 36% excise tax, which came into effect on November 1, 2022.

    Operating expenses were RMB145.0 million (US$19.9 million) in the third quarter of 2023, compared with RMB56.8 million in the same period of 2022. The increase was primarily due to the changes in share-based compensation expenses, which were RMB24.8 million (US$3.4 million) in the third quarter of 2023, compared with positive RMB176.6 million in the same period of 2022. The changes in share-based compensation expenses consisted of (i) positive RMB4.0 million (US$0.6 million) recognized in selling expenses, (ii) RMB29.8 million (US$4.1 million) recognized in general and administrative expenses, and (iii) positive RMB0.9 million (US$0.1 million) recognized in research and development expenses. The changes in share-based compensation expenses were primarily due to the changes in the fair value of the share incentive awards that the Company granted to its employees with the fluctuations of the Company's share price.

    Selling expenses were RMB39.7 million (US$5.4 million) in the third quarter of 2023, compared with RMB52.5 million in the same period of 2022, primarily due to the decrease in salaries and welfare benefits.

    General and administrative expenses were RMB74.5 million (US$10.2 million) in the third quarter of 2023, compared with positive RMB41.7 million in the same period of 2022, mainly driven by the changes in share-based compensation expenses.

    Research and development expenses were RMB30.8 million (US$4.2 million) in the third quarter of 2023, compared with RMB46.0 million in the same period of 2022, mainly driven by the decrease in salaries and welfare benefits.

    Loss from operations was RMB39.3 million (US$5.4 million) in the third quarter of 2023, compared with profit from operations of RMB465.2 million in the same period of 2022.

    Income tax expense was RMB0.5 million (US$0.1 million) in the third quarter of 2023, compared with RMB70.9 million in the same period of 2022.

    U.S. GAAP net income was RMB172.7 million (US$23.7 million) in the third quarter of 2023, compared with RMB505.2 million in the same period of 2022.

    Non-GAAP net income was RMB197.5 million (US$27.1 million) in the third quarter of 2023, compared with RMB328.6 million in the same period of 2022.

    U.S. GAAP basic and diluted net income per American depositary share ("ADS") were RMB0.130 (US$0.018) and RMB0.127 (US$0.017) in the third quarter of 2023, compared with U.S. GAAP basic and diluted net income per ADS of RMB0.381 and RMB0.379, respectively, in the same period of 2022.

    Non-GAAP basic and diluted net income per ADS[2] were RMB0.149 (US$0.020) and RMB0.146 (US$0.020), respectively, in the third quarter of 2023, compared with non-GAAP basic and diluted net income per ADS of RMB0.247 and RMB0.246, respectively, in the same period of 2022.

    [2] Non-GAAP basic and diluted net income per ADS is a non-GAAP financial measure. For more information on the Company's non-GAAP financial measures, please see the section "Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

    Balance Sheet and Cash Flow

    As of September 30, 2023, the Company had cash and cash equivalents, restricted cash, short-term bank deposits, net, short-term investments, long-term bank deposits, net and long-term investment securities, net of RMB15,132.5 million (US$2,074.1 million), compared with RMB15,786.6 million as of June 30, 2023. For the third quarter ended September 30, 2023, net cash generated from operating activities was RMB67.5 million (US$9.2 million).

    Recent Development

    To catch potential growth opportunities in the international market, on November 10, 2023, the Company terminated an existing non-competition agreement with Relx Inc., which had been entered into on December 16, 2020. The termination of this agreement gives the Company the flexibility to build an international presence in the future by conducting tobacco harm reduction product business outside China.

    Dividend Payment

    The Company announced that its Board of Directors approved a cash dividend of US$0.01 per ordinary share, or US$0.01 per ADS, to holders of ordinary shares and holders of ADSs, respectively, as of the close of business on December 1, 2023 Beijing/Hong Kong Time and New York Time, respectively, payable in U.S. dollars. The payment date is expected to be on or around December 15, 2023 and on or around December 22, 2023 for holders of ordinary shares and holders of ADSs, respectively.

    Conference Call

    The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 13, 2023 (8:00 PM Beijing/Hong Kong Time on November 13, 2023).

    Dial-in details for the earnings conference call are as follows:

    United States (toll-free):

    +1-888-317-6003

    International:

    +1-412-317-6061

    Hong Kong, China (toll-free):

    +800-963-976

    Hong Kong, China:

    +852-5808-1995

    Mainland China:

    400-120-6115

    Participant Code:

    4247290

    Participants should dial in 10 minutes before the scheduled start time and ask to be connected to the call for "RLX Technology Inc." with the Participant Code as set forth above.

    Additionally, a live and archived webcast of the conference call will be available on the Company's investor relations website at https://ir.relxtech.com.

    A replay of the conference call will be accessible approximately two hours after the conclusion of the call until November 20, 2023, by dialing the following telephone numbers:

    United States:

    +1-877-344-7529

    International:

    +1-412-317-0088

    Replay Access Code:

    9409580

    About RLX Technology Inc.

    RLX Technology Inc. (NYSE:RLX) is a leading branded e-vapor company in China. The Company leverages its strong in-house technology, product development capabilities, and in-depth insights into adult smokers' needs to develop superior e-vapor products.

    For more information, please visit: http://ir.relxtech.com.

    Non-GAAP Financial Measures

    The Company uses non-GAAP net income and non-GAAP basic and diluted net income per ADS, each a non-GAAP financial measure, in evaluating its operating results and for financial and operational decision-making purposes. Non-GAAP net income represents net income excluding share-based compensation expenses. Non-GAAP basic and diluted net income per ADS is computed using non-GAAP net income attributable to RLX Technology Inc. and the same number of ADSs used in U.S. GAAP basic and diluted net income per ADS calculation.

    The Company presents these non-GAAP financial measures because they are used by the management to evaluate its operating performance and formulate business plans. The Company believes that they help identify underlying trends in its business that could otherwise be distorted by the effect of certain expenses that are included in net income. The Company also believes that the use of the non-GAAP measures facilitates investors' assessment of its operating performance, as they could provide useful information about its operating results, enhances the overall understanding of its past performance and future prospects and allows for greater visibility with respect to key metrics used by the management in its financial and operational decision making.

    The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. They should not be considered in isolation or construed as an alternative to net income, basic and diluted net income per ADS or any other measure of performance or as an indicator of its operating performance. Investors are encouraged to review its historical non-GAAP financial measures to the most directly comparable U.S. GAAP measures. The non-GAAP financial measures here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. The Company encourages investors and others to review its financial information in its entirety and not rely on any single financial measure.

    For more information on the non-GAAP financial measures, please see the table captioned "Unaudited Reconciliation of GAAP and non-GAAP Results" set forth at the end of this press release.

    Exchange Rate Information

    This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB are made at a rate of RMB7.2960 to US$1.00, the exchange rate on September 29, 2023, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or U.S. dollar amounts referred could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all.

    Safe Harbor Statement

    This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" and similar statements. Among other things, quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward- looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's growth strategies; its future business development, results of operations and financial condition; trends and competition in China's e-vapor market; changes in its revenues and certain cost or expense items; PRC governmental policies, laws and regulations relating to the Company's industry, and general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is current as of the date of this press release, and the Company does not undertake any obligation to update such information, except as required under applicable law.

    For more information, please contact:

    In China:

    RLX Technology Inc.

    Head of Capital Markets

    Sam Tsang

    Email: [email protected] 

    Piacente Financial Communications

    Jenny Cai

    Tel: +86-10-6508-0677

    Email: [email protected] 

    In the United States:

    Piacente Financial Communications

    Brandi Piacente

    Tel: +1-212-481-2050

    Email: [email protected] 

     

    RLX TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    (All amounts in thousands)











    As of



    December 31,

    September 30,

    September 30,



    2022

    2023

    2023



    RMB

    RMB

    US$

    ASSETS







    Current assets:







    Cash and cash equivalents

    1,268,512

    2,523,977

    345,940

    Restricted cash

    20,574

    53,207

    7,293

    Short-term bank deposits, net

    7,084,879

    3,156,599

    432,648

    Receivables from online payment platforms

    3,000

    4,362

    598

    Short-term investments

    2,434,864

    2,568,599

    352,056

    Accounts and notes receivable, net

    51,381

    84,023

    11,516

    Inventories

    130,901

    78,323

    10,735

    Amounts due from related parties

    5,112

    155,540

    21,319

    Prepayments and other current assets, net

    198,932

    488,636

    66,973

    Total current assets

    11,198,155

    9,113,266

    1,249,078

    Non-current assets:







    Property, equipment and leasehold improvement, net

    87,871

    67,829

    9,297

    Intangible assets, net

    7,552

    5,988

    821

    Long-term investments, net

    8,000

    434,949

    59,615

    Deferred tax assets, net

    63,894

    63,894

    8,758

    Right-of-use assets, net

    75,008

    57,883

    7,934

    Long-term bank deposits, net

    1,515,428

    2,659,451

    364,508

    Long-term investment securities, net

    3,409,458

    4,170,629

    571,632

    Other non-current assets, net

    13,458

    6,054

    830

    Total non-current assets

    5,180,669

    7,466,677

    1,023,395

    Total assets

    16,378,824

    16,579,943

    2,272,473









    LIABILITIES AND SHAREHOLDERS' EQUITY







    Current liabilities:







    Accounts and notes payable

    269,346

    240,001

    32,895

    Contract liabilities

    75,226

    68,253

    9,355

    Salary and welfare benefits payable

    127,749

    80,961

    11,097

    Taxes payable

    109,676

    82,460

    11,302

    Amounts due to related parties

    423

    -

    -

    Accrued expenses and other current liabilities

    161,455

    105,839

    14,507

    Lease liabilities - current portion

    45,955

    35,703

    4,894

    Total current liabilities

    789,830

    613,217

    84,050









    Non-current liabilities:







    Deferred tax liabilities

    8,653

    8,653

    1,186

    Lease liabilities - non-current portion

    39,968

    29,612

    4,059

    Total non-current liabilities

    48,621

    38,265

    5,245

    Total liabilities

    838,451

    651,482

    89,295

















    Shareholders' Equity:







    Total RLX Technology Inc. shareholders' equity

    15,569,060

    15,942,807

    2,185,144

    Noncontrolling interests

    (28,687)

    (14,346)

    (1,966)

    Total shareholders' equity

    15,540,373

    15,928,461

    2,183,178









    Total liabilities and shareholders' equity

    16,378,824

    16,579,943

    2,272,473

     

     

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF

    COMPREHENSIVE INCOME

    (All amounts in thousands, except for share and per share data)





















    For the three months ended



    For the nine months ended



    September 30,

    June 30,

    September 30,

    September 30,



    September 30,

    September 30,

    September 30,



    2022

    2023

    2023

    2023



    2022

    2023

    2023



    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$



















       Net revenues

    1,044,424

    378,123

    428,069

    58,672



    4,992,767

    995,069

    136,386

       Cost of revenues

    (522,451)

    (171,733)

    (222,056)

    (30,435)



    (2,835,908)

    (472,482)

    (64,759)

       Excise tax on products

    -

    (107,853)

    (100,313)

    (13,749)



    -

    (272,624)

    (37,366)

       Gross profit

    521,973

    98,537

    105,700

    14,488



    2,156,859

    249,963

    34,261



















       Operating expenses:

















       Selling expenses

    (52,544)

    (45,226)

    (39,698)

    (5,441)



    (251,125)

    (170,685)

    (23,394)

       General and administrative expenses

    41,746

    41,368

    (74,519)

    (10,213)



    (182,604)

    (289,655)

    (39,701)

       Research and development expenses

    (45,978)

    (43,317)

    (30,785)

    (4,218)



    (187,552)

    (150,784)

    (20,667)

       Total operating expenses

    (56,776)

    (47,175)

    (145,002)

    (19,872)



    (621,281)

    (611,124)

    (83,762)



















       Income/(loss) from operations

    465,197

    51,362

    (39,302)

    (5,384)



    1,535,578

    (361,161)

    (49,501)



















       Other income:

















       Interest income, net

    56,237

    162,888

    158,259

    21,691



    126,112

    469,950

    64,412

       Investment income  

    38,104

    20,588

    21,028

    2,882



    110,974

    63,001

    8,635

       Others, net

    16,573

    21,380

    33,246

    4,557



    249,016

    183,783

    25,190

       Income before income tax

    576,111

    256,218

    173,231

    23,746



    2,021,680

    355,573

    48,736

       Income tax expense 

    (70,871)

    (51,502)

    (534)

    (73)



    (387,823)

    (34,465)

    (4,724)

       Net income

    505,240

    204,716

    172,697

    23,673



    1,633,857

    321,108

    44,012

       Less: net income/(loss) attributable to noncontrolling

    interests

    1,883

    1,929

    1,709

    234



    (35,842)

    4,299

    589

       Net income attributable to RLX Technology Inc.

    503,357

    202,787

    170,988

    23,439



    1,669,699

    316,809

    43,423

       Other comprehensive income/(loss):

















       Foreign currency translation adjustments

    618,060

    563,078

    (81,069)

    (11,111)



    1,152,674

    333,913

    45,767

       Unrealized income on long-term investment securities

    -

    5,539

    3,508

    481



    -

    11,920

    1,634

       Total other comprehensive income/(loss)

    618,060

    568,617

    (77,561)

    (10,630)



    1,152,674

    345,833

    47,401

       Total comprehensive income

    1,123,300

    773,333

    95,136

    13,043



    2,786,531

    666,941

    91,413

       Less: total comprehensive income/(loss) attributable to

    noncontrolling interests

    1,883

    1,929

    1,709

    234



    (35,842)

    4,299

    589

       Total comprehensive income attributable to RLX

    Technology Inc.

    1,121,417

    771,404

    93,427

    12,809



    2,822,373

    662,642

    90,824



















       Net income per ordinary share/ADS 

















       Basic

    0.381

    0.154

    0.130

    0.018



    1.258

    0.241

    0.033

       Diluted

    0.379

    0.150

    0.127

    0.017



    1.244

    0.236

    0.032



















       Weighted average number of ordinary shares/ADSs

















       Basic

    1,322,824,853

    1,318,628,588

    1,316,452,743

    1,316,452,743



    1,327,552,588

    1,317,292,081

    1,317,292,081

       Diluted

    1,329,164,753

    1,353,296,802

    1,344,359,144

    1,344,359,144



    1,341,861,541

    1,344,018,578

    1,344,018,578

     

    RLX TECHNOLOGY INC.

    UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS

    (All amounts in thousands, except for share and per share data, or otherwise noted)













    For the three months ended



    For the nine months ended



    September 30,

    June 30,

    September 30,

    September 30,



    September 30,

    September 30,

    September 30,



    2022

    2023

    2023

    2023



    2022

    2023

    2023



    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$

    Net income

    505,240

    204,716

    172,697

    23,673



    1,633,857

    321,108

    44,012

    Add: share-based compensation expenses

















           Selling expenses

    (24,189)

    (15,338)

    (4,045)

    (554)



    (48,232)

    4,571

    627

           General and administrative expenses

    (128,200)

    (90,923)

    29,771

    4,080



    (207,219)

    140,190

    19,215

           Research and development expenses

    (24,242)

    (12,229)

    (936)

    (128)



    (53,240)

    1,490

    204

    Non-GAAP net income

    328,609

    86,226

    197,487

    27,071



    1,325,166

    467,359

    64,058



















    Net income attributable to RLX Technology Inc.

    503,357

    202,787

    170,988

    23,439



    1,669,699

    316,809

    43,423

    Add: share-based compensation expenses

    (176,631)

    (118,490)

    24,790

    3,398



    (308,691)

    146,251

    20,046

    Non-GAAP net income attributable to RLX

        Technology Inc.

    326,726

    84,297

    195,778

    26,837



    1,361,008

    463,060

    63,469



















    Non-GAAP net income per ordinary share/ADS

















    - Basic

    0.247

    0.064

    0.149

    0.020



    1.025

    0.352

    0.048

    - Diluted

    0.246

    0.062

    0.146

    0.020



    1.014

    0.345

    0.047

    Weighted average number of ordinary shares/ADSs

















    - Basic

    1,322,824,853

    1,318,628,588

    1,316,452,743

    1,316,452,743



    1,327,552,588

    1,317,292,081

    1,317,292,081

    - Diluted

    1,329,164,753

    1,353,296,802

    1,344,359,144

    1,344,359,144



    1,341,861,541

    1,344,018,578

    1,344,018,578

     

     

    RLX TECHNOLOGY INC.



    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS



    (All amounts in thousands)

























    For the three months ended



    For the nine months ended





    September 30,

    June 30,

    September 30,

    September 30,



    September 30,

    September 30,

    September 30,





    2022

    2023

    2023

    2023



    2022

    2023

    2023





    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$



    Net cash (used in)/generated from operating activities

    (1,016,862)

    41,339

    67,452

    9,245



    735,695

    (121,895)

    (16,707)



    Net cash generated from/(used in) investing activities

    211,064

    431,683

    967,342

    132,585



    (4,885,585)

    1,780,979

    244,103



    Net cash used in financing activities

    (19,822)

    (199,080)

    (229,492)

    (31,454)



    (326,623)

    (424,226)

    (58,145)



    Effect of foreign exchange rate changes on cash,

        cash equivalents and restricted cash

    22,772

    48,393

    (5,562)

    (762)



    173,813

    53,240

    7,298



    Net (decrease)/increase in cash and cash

        equivalents and restricted cash

    (802,848)

    322,335

    799,740

    109,614



    (4,302,700)

    1,288,098

    176,549



    Cash, cash equivalents and restricted cash at

        the beginning of the period

    1,709,615

    1,455,109

    1,777,444

    243,619



    5,209,467

    1,289,086

    176,684



    Cash, cash equivalents and restricted cash at

    the end of the period

    906,767

    1,777,444

    2,577,184

    353,233



    906,767

    2,577,184

    353,233



     

    Cision View original content:https://www.prnewswire.com/news-releases/rlx-technology-announces-unaudited-third-quarter-2023-financial-results-301985709.html

    SOURCE RLX Technology Inc.

    Get the next $RLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLX

    DatePrice TargetRatingAnalyst
    3/17/2025$2.80 → $2.50Buy → Neutral
    Citigroup
    8/8/2023$2.60Buy
    UBS
    More analyst ratings

    $RLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RLX Technology downgraded by Citigroup with a new price target

    Citigroup downgraded RLX Technology from Buy to Neutral and set a new price target of $2.50 from $2.80 previously

    3/17/25 7:42:34 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    UBS initiated coverage on RLX Technology with a new price target

    UBS initiated coverage of RLX Technology with a rating of Buy and set a new price target of $2.60

    8/8/23 9:12:45 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RLX Technology Extends US$500 Million Share Repurchase Program

    SHENZHEN, China, Dec. 31, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that its board of directors has authorized the extension of its existing share repurchase program for an additional 24-month period through December 31, 2027. The existing share repurchase program was established in December 2021 and extended in December 2023. Under the current share repurchase program, the Company may repurchase up to US$500 million of its ordinary shares represented by ADSs until December 31, 2025. As of December 31, 2025, the Company had cumulatively repurchased approximately 170 million ordinary share

    12/31/25 3:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Announces Unaudited Third Quarter 2025 Financial Results

    SHENZHEN, China, Nov. 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Net revenues were RMB1,129.3 million (US$158.6 million) in the third quarter of 2025, compared with RMB756.3 million in the same period of 2024.Gross margin was 31.2% in the third quarter of 2025, compared with 27.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB187.8 million (US$26.4 million) in the third quarter of 2025, compared with RMB84.0 million in the same period of 2024.U

    11/14/25 4:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology to Report Third Quarter 2025 Financial Results on November 14, 2025

    - Earnings Call Scheduled for 7:00 a.m. ET on November 14, 2025 - SHENZHEN, China, Nov. 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025, before the U.S. markets open on Friday, November 14, 2025. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 14, 2025 (8:00 PM Beijing/Hong Kong Time on November 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-

    11/3/25 1:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    SEC Filings

    View All

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    12/31/25 6:03:48 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    11/14/25 6:02:26 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    8/22/25 7:09:03 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Financials

    Live finance-specific insights

    View All

    RLX Technology Announces Unaudited Third Quarter 2025 Financial Results

    SHENZHEN, China, Nov. 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Net revenues were RMB1,129.3 million (US$158.6 million) in the third quarter of 2025, compared with RMB756.3 million in the same period of 2024.Gross margin was 31.2% in the third quarter of 2025, compared with 27.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB187.8 million (US$26.4 million) in the third quarter of 2025, compared with RMB84.0 million in the same period of 2024.U

    11/14/25 4:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology to Report Third Quarter 2025 Financial Results on November 14, 2025

    - Earnings Call Scheduled for 7:00 a.m. ET on November 14, 2025 - SHENZHEN, China, Nov. 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025, before the U.S. markets open on Friday, November 14, 2025. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 14, 2025 (8:00 PM Beijing/Hong Kong Time on November 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-

    11/3/25 1:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Announces Unaudited Second Quarter 2025 Financial Results

    SHENZHEN, China, Aug. 22, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Net revenues were RMB880.0 million (US$122.8 million) in the second quarter of 2025, compared with RMB627.2 million in the same period of 2024.Gross margin was 27.5% in the second quarter of 2025, compared with 25.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB116.2 million (US$16.2 million) in the second quarter of 2025, compared with RMB46.9 million in the same period of 2024.U.S

    8/22/25 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/7/24 6:06:29 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/6/24 4:01:28 PM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/14/23 6:01:42 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care